Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Investing.com -- Sanofi (EPA:SASY)(NASDAQ:SNY) has entered into exclusive negotiations with private equity firm Clayton, Dubilier&Rice to sell a controlling stake in its consumer healthcare unit ...

PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French ...

French pharmaceutical group Sanofi and US private equity firm Clayton Dubilier & Rice (CD&R) have entered exclusive negotiations regarding the partial takeover of Sanofi subsidiary Opella.